Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
RESEARCH TOOLSreports
Aquestive Therapeutics (AQST) Stock Price & Analysis
1,617 Followers
AQST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.72 - $2.69
Previous Close$1.53
Volume135.61K
Average Volume (3M)322.20K
Market Cap
$102.09M
Enterprise Value$124.78M
Total Cash (Recent Filing)$22.44M
Total Debt (Recent Filing)$45.12M
Price to Earnings (P/E)-3.4
Beta1.91
Next Earnings
Nov 07, 2023EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding61,726,668
10 Day Avg. Volume285,875
30 Day Avg. Volume322,203
Standard Deviation0.33
R-Squared0.18
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.86
Price to Sales (P/S)7.13
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit2.62
Enterprise Value/Ebitda-8.71
Forecast
1Y Price Target
$5.67Price Target Upside270.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Aquestive Therapeutics News
Pre-EarningsAQST Earnings this Week: How Will it Perform?
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $0.72 and its highest was $2.69 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Currently, no data Available
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Nov 07, 2023 which is in 37 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Aug 07, 2023. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.117 by $0.017.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -$0.11.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 66,727,295 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.117. Following the earnings report the stock price went down -5.366%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Among the largest hedge funds holding Aquestive Therapeutics’s share is Caxton Associates LP. It holds Aquestive Therapeutics’s shares valued at N/A.
---
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (270.59% Upside)
$5.67 (270.59% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
---
Top 5 ETFs holding AQST
Vanguard Total Stock Market ETF
$1.67M
Up to five ETFs with an Outperform Smart Score that hold AQST. The ETFs are listed according to market value of AQST within the ETF
---